Target intelligence / Profile preview

Protein Argonaute-2 (AGO2) (AGO2)

Target
AGO2
Molecular classification
Enzyme, Ribonucleoprotein
01

Overview

The RNA-induced silencing complex (RISC) is a multi-protein assembly that serves as the fundamental effector of the RNA interference (RNAi) pathway in eukaryotic cells (UniProt P98170). The core catalytic component of this complex is Protein Argonaute-2 (Ago2), a specialized endonuclease that utilizes small interfering RNAs (siRNAs) or microRNAs (miRNAs) as templates to identify complementary messenger RNA (mRNA) sequences. Upon binding to a target mRNA, the PIWI domain of Ago2 facilitates the site-specific cleavage of the transcript, leading to its rapid degradation and the subsequent silencing of the encoded protein. This mechanism is highly conserved and plays a critical role in regulating gene expression, defending against viral infections, and maintaining genomic stability. In modern medicine, RISC/Ago2 is the primary target for siRNA-based therapeutics, which are designed to hijack this endogenous machinery to selectively downregulate disease-causing genes. Approved drugs such as Patisiran and Inclisiran utilize this pathway to treat conditions ranging from hereditary amyloidosis to hypercholesterolemia by delivering synthetic siRNAs that load into the RISC (FDA Prescribing Information). However, therapeutic development must address challenges such as off-target effects, where the complex silences unintended genes, and the potential for saturating the cell's natural RNAi capacity.

Other names
Argonaute-2AGO2EIF2C2SlicerRISCRNA-induced silencing complexEukaryotic translation initiation factor 2C 2hAgo2
02

Mechanism of action

RNA interference (RNAi) mediated by the sequence-specific cleavage of target mRNA by the endonuclease activity of Argonaute-2.

03

Biological functions

Gene silencingRNA interferencemRNA degradationTranslational repressionmiRNA processing
04

Disease associations

CancerGenetic diseaseViral infectionMetabolic disorderHereditary transthyretin-mediated amyloidosisHypercholesterolemia
05

Safety considerations

Off-target gene silencingSaturation of endogenous miRNA pathwaysInnate immune activationLiver enzyme elevations
06

Interacting drugs

8 more in the full profile.

07

Biomarkers

Target mRNA expression levelsCirculating target protein levelsRISC-associated guide RNA concentration

Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on Protein Argonaute-2 (AGO2) (AGO2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protein Argonaute-2 (AGO2) (AGO2).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call